

GUINEA BISSAU COVAX TA PLAN				Milestones			Budget for 2020			
Country	Programmatic Area	Activity	Partner	January 2021	March 2021	June 2021	Expected Duration of Activity	Expected Outcome	Please specify detailed budget assumptions including i. FTEs of proposed consultants, where applicable - this	TOTAL
Guinea-Bissau	Demand Generation & Communication	J.1 Design a demand plan (includes advocacy, communications, social mobilization, risk and safety comms, community engagement, and training) to generate confidence, acceptance and demand for COVID-19 vaccines. Must include a crisis communications preparedness planning	UNICEF			Demand plan (includes advocacy, communications, social mobilization, risk and safety comms, community engagement, and training) designed.	more than 3 months	Target populations accept and demand for COVID-19 vaccines	Fee for 1 international consultant x 6 months + travel + workshop	\$187,552.80
Guinea-Bissau	Planning & Coordination	A.7 Identify and plan for the national vaccine access/procurement approach (e.g. COVAX Facility, bilateral purchase agreement, procurement through UN agency, self-procurement) and complete required paperwork. (Additional information to follow)	UNICEF		National vaccine access/procurement approach identified and planned for, and the relevant paperwork is completed.		0-1 month	An adapted national vaccine procurement approach available	DSA 2 UNICEF RO support x 10 days DSA/Travel + workshop +	
Guinea-Bissau	Service Delivery	E.2 Identify potential COVID-19 vaccine delivery strategies leveraging both existing vaccination platforms and non-vaccination delivery approaches to best reach identified target groups	UNICEF			Potential COVID-19 vaccine delivery strategy identified to best reach target groups.	more than 3 months	Vaccines delivered according planned timeline and location	One national consultant x 3months + travel + workshop	
Guinea-Bissau	Vaccine, Cold Chain & Logistics	H.1 Establish/strengthen the national logistics working group with appropriate terms of reference and standard operating procedures to coordinate COVID-19 vaccines and ancillary products deployment	UNICEF		National logistics working group with appropriate terms of reference and standard operating procedures to coordinate COVID-19 vaccines and ancillary products deployment established/strengthened.		more than 3 months	National Logistic group fully operational	One international consultant x 3 months + travel + workshop	\$180,991.57
Guinea-Bissau	Monitoring & Evaluation	G.2 Develop or adapt necessary monitoring tools or adapt existing tools: vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) and analytical tools to monitor progress and coverage among different at-risk categories	UNICEF			Necessary monitoring tools developed or existing tools (vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) adapted and analytical tools to monitor progress and coverage among different at-risk categories developed.	more than 3 months	monitoring and analytical tools developed	One national consultant x 4 months + workshop	
Guinea-Bissau	Planning & Coordination	A.6 Develop the National Deployment and Vaccination Plan (NDVP) with input from relevant bodies (National COVID-19 Response Coordinating Committee, CNCC, CTWG, NITAG, National Immunization Programme, National Regulatory Authority, AEFI committee and other relevant groups such as private sector). The NDVP should be in line with WHO guidance and SAGE recommendations (plan can be developed by adapting the Pandemic Influenza NDVP, if existing).	WHO		NDVP developed with input from relevant bodies (National COVID-19 Response Coordinating Committee, CNCC, CTWG, NITAG, National Immunization Programme, National Regulatory Authority, AEFI committee and other relevant groups such as private sector), in line with WHO guidance and SAGE recommendation.		more than 3 months	The national deployment and vaccination plan developed and implemented in partnership framework	one national consultant x3 months + workshop	
Guinea-Bissau	Training & Supervision	F.1 Develop a training plan to prepare for COVID-19 vaccine introduction that includes key groups of participants, content topic areas, key training partners and training methods (in-person or virtual). WHO will provide a template for guidance	WHO		Training plan to prepare for COVID-19 vaccine introduction that includes key groups of participants, content topic areas, key training partners and training methods (in-person or virtual) developed.		more than 3 months	The training plan developed and the trainings carried out countrywide	one international consultant x 3 months + travel + workshop	
Guinea-Bissau	Prioritization, Targeting & Covid-19 Surveillance	D.3 Coordinate with national COVID-19 disease surveillance group to ensure relevant epidemiological data will be collected to inform planning of subsequent rounds of COVAX vaccination, including outbreak responses	WHO			Ensure relevant epidemiological data is collected in coordination with national COVID-19 disease surveillance group.	more than 3 months	Accurate epidemiological covid-19 surveillance data available and used for decision making	one international consultant x 6 months + travel + workshop	
Guinea-Bissau	Monitoring & Evaluation	G.1 Develop or adapt existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc. ) for COVID-19 vaccine. Determine whether registration and reporting will be individual or aggregate, and to what extent existing tools and systems can be re-used	WHO		Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc. ) for COVID-19 vaccine developed or adapted.		1-2 months	The existing surveillance and monitoring framework adapted	one international consultant x 2 months + travel + workshop	
Guinea-Bissau	Safety Surveillance	I.5 Plan active surveillance of specific COVID-19 vaccine related adverse events. If this is not possible, develop provisions that allow reliance on active surveillance data, decisions, and information from other countries or regional or international bodies.	WHO		Active surveillance of specific COVID-19 vaccine related adverse events is planned for		more than 3 months	The active surveillance of specific COVID-19 AEFI plan developed and implemented	one international consultant x 3 months + travel + workshop	

